Shalby/SE/2024‐25/77 October 30, 2024

The Listing Department Corporate Service Department

National Stock Exchange of India Ltd BSE Limited
Mumbai 400 051. Mumbai 400 001.

Scrip Code : SHALBY Scrip Code: 540797

Through : https://neaps.nseindia.com/NEWLISTINGCORP/ Through : http://listing.bseindia.com

Sub: Investor Presentation for the Quarter ended 30th September 2024

Dear Sir / Madam,

We are submitting herewith Investor Presentation on financial & operational performance of the
Company for the quarter year ended September 30, 2024, which will be discussed at the Investor
Conference call scheduled today i.e. on October 30, 2024.

The said Investor Presentation is being uploaded on website of our Company at

https://www.shalby.org/investors/  Investors Presentation.

You are requested to take the same on your record.

Thanking you,

Yours sincerely
For Shalby Limited
TUSHAR Digitally signed by
TUSHAR
DINESHCHAND DINESHCHANDRA SHAH
Date: 2024.10.30 14:02:04
RA SHAH +05'30'

Tushar Shah
AVP & Company Secretary
Mem. No: FCS‐7216

Encl.: as above
Investor Presentation

Q2 & H1 FY2025
AGENDA

01 SHALBY GROUP QUARTERLY AND ANNUAL PERFORMANCE

PERFORMANCE

02 HOSPITAL BUSINESS QUARTERLY AND ANNUAL PERFORMANCE

PERFORMANCE

03 HOMECARE BUSINESS QUARTERLY PERFORMANCE

04 FRANCHISE BUSINESS QUARTERLY PERFORMANCE

05 SHALBY ACADEMY QUARTERLY PERFORMANCE

06 IMPLANT BUSINESS QUARTERLY PERFORMANCE

2
Financials Snapshot Q2 FY25

Consolidated Revenue at ₹ 2,747 mn in Q2 FY25 vs ₹ 2,434 mn in Q2 FY24

Consolidated EBITDA at ₹ 398 mn in Q2 FY25 vs ₹ 581 mn in Q2 FY24
Consolidated Consolidated PBT at ₹ 137 mn in Q2 FY25 vs ₹ 426 mn in Q2 FY24
Financial Highlights
Consolidated Net debt stood at Rs.2,047 mn as on September’24
Consolidated Annualized ROCE for H1’FY25 stood at 10.4%

Standalone Revenue at ₹ 2,176 mn in Q2 FY25 vs ₹ 2,228 mn in Q2 FY24

Standalone EBITDA at ₹ 408 mn in Q2 FY25 vs ₹ 575 mn in Q2 FY24
Standalone Standalone PBT at ₹ 283 mn in Q2 FY25 vs ₹ 473 mn in Q2 FY24
Financial Highlights
Standalone Net cash stood at Rs.742 mn as on September’24
Standalone Annualized ROCE for H1’FY25 stood at 15%

3
 Consolidated Performance Highlights – Q2 FY25

Revenue (INR MN) EBITDA1 & Margin (INR MN)

2747
581

398

2434

23.9% 14.4%

Q2 FY24 Q2 FY25 Q2 FY24 Q2 FY25

Up 12.9% Down 31.5%

4
1. EBITDA includes other income
 Consolidated Performance Highlights – H1 FY25

Revenue (INR MN) EBITDA1 & Margin (INR MN)

5633
1058

4834 947

21.9% 16.8%

H1 FY24 H1 FY25 H1 FY24 H1 FY25

Up 16.5% Down 10.4%

5
1. EBITDA includes other income
 Consolidated P/L & B/S – Q2 FY25

Profit & Loss (INR Mn) Balance Sheet (INR Mn)

Gross 4057
Q2 Q2 Y-o-Y Borrowings
Particulars (Rs. Millions)
FY25 FY24 Growth

Cash & Cash 2010

Equivalents
Revenue 2,747 2,434 12.9%

Net Cash/(Debt) (2,047)

EBITDA 398 581 (31.5%)

EBITDA Margin % 14.4% 23.9% ROCE1 10.4%

PBT 137 426 (67.8%)

Debt/Equity 0.20x
PBT Margin % 4.9% 17.5%

Notes: 6
1. ROCE= Annualized EBIT/ Average (Equity +Debt- Cash & Cash Equivalent)
 Hospital Business Highlights Q2 FY25
Global leader in Joint replacements with more than 1,50,000 surgeries

Surgery Count and YoY Growth Operational Performance

Q2 Q2 YoY
Particulars
FY255 FY24 Growth

Arthroplasty Nephro & Urology

In-Patient1 (Nos.) 23.907 22,652 5.54%
3140+ 17.1% 680+ 7.9%
Out Patient2 (Nos.) 1,43,261 1,26,407 13.33%

Surgeries Count 7,646 7,771 1.6%

Oncology General & Cosmetics ARPOB3 ( In Rs.) 38,779 36,136 7.31%

520+ 9.8% 840+ 11.0%

Operational Beds4 (Nos.) 1,415 1,260 12.3%

Occupied Beds 690 678 1.77%

Occupancy Rate 49% 54% 510bps

Orthopaedic Other Surgery
1070+ 44.9% 1370+ 9.7% ALOS (without Daycare) 3.6 3.92 (8.2)%
Notes:
1. In-Patient count Includes Day care count 2. Out-Patient Count is excluding Vaccination counts 3. ARPOB excludes vaccination 4. Included operational beds in (FOSO) SOCE unit 5.Q2’FY25 numbers includes PK Healthcare performance
6. Occupancy Rate excluding PK Healthcare is 51%,. 7
 Hospital Business Highlights

Specialty Revenue Mix

Q2 FY2024 Q2 FY20252

Others, 12% Arthroplasty,

Others, 14%
Arthroplasty, 34%
Nephrology, 5%
42%
Nephrology,
6%

Neurology, 5%

Neurology,
6%
Orthopaedic,
7%

Orthopaedic,
9% Critical Care
Oncology, 11% & General
Critical Care & Medicine,
General Oncology, 12%
Medicine, 11% 10% Cardiac
Cardiac Science, 10%
Science, 8%

Notes: 8
1. Orthopedic includes Spine 2.Q2’FY25 numbers includes PK Healthcare performance.
 Hospital Business Highlights

Payor Mix

Q2 FY2024 Q2 FY20251

Government,
21.2% Self Pay, Government, Self Pay,
34.6% 22.7% 36.4%

Insurance, Insurance,
44.2% 40.9%

Notes: 9
1. .Q2’FY25 numbers includes PK Healthcare performance.
High Growth Business Verticals
Healthcare Conglomerate

Building An Integrated Orthopedic Solutions Ecosystem

Multi-Specialty Franchise Implant

11 Hospitals across western, northern 5 Hospital network USA based Knee & Hip
and central India Manufacturing facility
Synergistic Sustainable Business Model

• Headroom to grow further with • An Asset light franchise model

existing bed capacity without major • Manufacturing US FDA

Diversification in Revenue Mix

will leverage Shalby expertise
capex approved implants to sell
across the US and international
• Shalby to monitor and control markets
• Ongoing diversification of the quality of the services
Arthroplasty with Cardiac, Onco & through FOSO and FOSM
Neuro-Science, Critical Care, business model • Highly experienced
General Medicine and Transplants management team appointed to
lead implant business
• Continue to maintain leadership in • These centers to be equipped
Joint Replacement by volume with the latest high-definition • Enables Shalby to procure high
arthroscopic systems and quality implants for its own
• Homecare and International establish state-of-the-art joint consumption in India
business further accelerate growth replacements facility

• Plans to open 40 SOCE across • Plans to become USD 100 mn

• Adopting and Leveraging India business
Technology to bring better medical
outcomes and patient reach

10
A Legend and Visionary Doctorpreneur behind Shalby

Dr Vikram I. Shah, the Founder of Shalby Ltd, is a world-renowned Joint

Replacement Surgeon who innovated “Zero Technique” that revolutionized Joint
Replacement Surgery.

A visionary entrepreneur, he transformed Shalby from a 6 bedded hospital in

1994 to an integrated healthcare group with 16 hospitals network and 2350+
beds across 13 cities in India with an implant manufacturing facility in California,
USA and distribution facility in India and South-East Asian countries.

Shalby is today the Biggest Corporate Hospital Group in Western and Central
India focusing on all major disciplines in medicine with credentials of being the
Largest Joint Replacement Centre of the World, having done over 1,50,000+
successful joint replacement surgeries till date.

Leveraging this expertise, he has envisioned establishing 40 Orthopedic

franchises in 30 cities in India.

Shalby Limited is listed on both the premier stock exchanges in India and has
Dr Vikram I Shah, the aspiration of growing multifold while preserving the core values of “Passion,
Founder & Chairman Compassion and Innovation”.

11
STANDALONE PERFORMANCE
(Hospital Business)

12
Standalone Business Highlights – Q2 FY25
Financial Performance
Revenue (INR Mn) EBITDA & Margin (INR Mn)

575
2228 2176

408

25.8% 18.7%

Q2 FY24 Q2 FY25 Q2 FY24 Q2 FY25

Down 2.4% Down 29.1%

PBT & Margin (INR Mn) ROCE (%)

473
18%

16%
283 15%

21.2% 12.9%

Q2 FY24 Q2 FY25 FY 23 FY 24 H1 FY25

(Annualised)
Down 40.3%
13
Standalone Business Highlights – H1 FY25
Financial Performance
Revenue (INR Mn) EBITDA & Margin (INR Mn)
4392 4580
1072
990

24.4% 21.6%

H1 FY24 H1 FY25 H1 FY24 H1 FY25

Up 4.2% Down 7.7%

PBT & Margin (INR Mn) PAT & Margin (INR Mn)
873
566
743
479

19.8% 16.2% 12.8% 10.4%

H1 FY24 H1 FY25 H1 FY24 H1 FY25

Down 14.9% Down 15.3%

14
 Standalone P&L and B/S – Q2 FY25

Profit & Loss (INR Mn) Total Revenue to EBITDA

120.0%

Q2 Q2
Particulars (Rs Mn) FY25 FY24 YoY Growth 100.0%
18.7% EBITDA
25.8%
80.0%
Materials and
24.3% Consumables
Total Revenue 2,176 2,228 (2.4%) 23.9%
60.0%
Fees to Doctors
and Consultants
25.8%
40.0% 23.3% Employee
EBITDA 408 575 (29.1%) Benefit Expenses

11.2%
13.3% Other Operative
20.0%
Expenses
8.6% 9.6%
Other expenses
7.2% 8.2%
EBITDA Margin % 18.7% 25.8% 0.0%
Q2’FY24 Q2’FY25

Balance Sheet as on September’24 (INR Mn)

PBT 283 473 (40.3%) Gross Borrowings 1,086

Cash & Cash Equivalents 1,828

Net Cash/(Debt) 742

PBT Margin % 12.9% 21.2% ROCE1 (annualized) 15%

Notes:
1. ROCE= Annualized EBIT/ Average (Equity +Debt- Cash & Cash Equivalent) 15
Standalone Business CAGR Growth

Shalby Continued to deliver high double-digit growth over the last 2 decades

Revenue (INR Mn) EBITDA (INR Mn)

8504 1982

6598
1426

3284 778

1685 439

194 22

FY 2007 FY 2012 FY 2017 FY 2022 FY 2024 FY 2007 FY 2012 FY 2017 FY 2022 FY 2024

16
 Shalby Sanar Q2’FY25 Highlights

Total
IP Count Employees 22500+
ARPOB 1110+ Sanar 370+ Patients
Total ₹85,722 International Expertise Served in
Revenue 54% in Liver, Doctors &
Centres :-
Consultant
FY23-24
of ₹25.74 OP Count revenue Total Bed Kidney,
Ethiopia 50+
Cr. in ALOS 3.64 3820+ generated Capacity Blood &
Iraq
Q2’FY25 vs from 130 Bone Nursing 1250+
Kenya
international 125+ Total
₹23.77 Cr. patients Kyrgyzstan Marrow
in Q1’FY25 Occupancy Patients Sulemania Transplant Support Surgeries
Rate 25% across 60+ Staff 135+ in 15+
Tajikistan
countries Uzbekistan Technician Specialties
50+

Notes:
ALOS is calculated without daycare. 17
Homecare Business Highlights Q2 FY 2025

Q2 FY2025 Highlights Patients Served (Nos)

Patients Served 9,080 in Q2 FY25 v/s 7,870 patients in Q2 FY24, grew by

15.3% YoY 9080

7,870
Revenue booked Rs.38.89 mn during Q2 FY25 v/s Rs.36.47 mn during Q2
FY24, grew by 6.6% YoY

Physio, Diagnostics and Pharmacy are the major revenue contributor in

Q2 FY24 Q2 FY25
Q2 FY25
Revenue (Rs Mn)
Industry Catalyst
38.89
• Providing services at 40+ Cities across India
36.47
• Provide Quality Services through high-end digital systems

• Less Chances of hospital acquired Infection

• Insurance Policies covering Home Healthcare Expenses

• Economical Homecare Services compared to Hospitals Q2 FY24 Q2 FY25

Shalby Homecare Comprehensive Services

ICU @Home | Diagnostic | Pharmacy | Medical Equipment | Doctor Visit | Nursing Care | Physiotherapy | Patient Attendant
18
 Clinical Update And Research Across Units during Q2 FY25
❖ Our commitment towards augmenting Shalby’s medical program has made notable strides in advancing our growth initiative from
single-specialty to multi-specialty by various brand awareness campaign , through digital platform and other various ATL model by
continuous investment in state of art medical equipment like EBUS (endobroncoscopy) setup for procedure used to diagnose different
type of inflammation, infection and cancer of Lungs. Radiation machine has been installed at Krishna Shalby Ahmedabad and Surat
Shalby.
Excellent Clinical outcome in rare and high end surgeries :-
▪ Left Microvascular Decomposition of Trigeminal Nerve under GA - A Case of Female 56 years old presented to Shalby hospital with
pain in left side of face from 2 years, c/o dry coughing from 4-days.Patient suffering from left sided trigeminal neuralgia. It was a very
rare case and complicated. Post operatively patient was vitally stable – SHALBY SURAT
▪ 3D VATS Uniportal Lt. Upper Lobectomy, Oncology - A case of Actinomycosis fungus since 4-5 yrs, Medical Treatment not
Effective, Recurrent Hematopoiesis. Upper lobectomy done with Uniportal Approach with 3D system Support – SHALBY SG
▪ Wertheims Surgery with Colectomy, Oncology - Very Advance Disease and involving Omentum, Bladder, Rectum, Sigmoid colon,
All resected with reconstruction and surgery completed with out any untoward event – SHALBY SG
▪ Kidney Transplant ( EF 15% Global Hypokinesia ) & Bilateral Limb Lengthening – SHALBY SANAR
▪ Cystoscopy + optical internal urethrotomy ( EF10% severe global hypokinesia + entire IVS inferior wall akinetic , LA/LV dilated ,
Grade 3 diastolic dysfunction , mild MR & PAH & TR/AR. ) – SHALBY SANAR
❖ 28 Transplants (12 Kidney,11 Liver & 5 Bone Marrow Transplant) during Q2 FY25 and with this we have performed 400+ Transplants
so far at our SG, Indore & Sanar units.
❖ 23 active clinical trials are ongoing across all hospitals, 46 upcoming clinical trials & 1 EC approval received, 1 Awaiting EC approval,
19
6 clinical trials are closed in Q2 FY25.
Key Focus Areas For Future In Hospital business
Global Leader in Joint Replacement with diversification in other specialties
• Continue to maintain global leadership in joint replacements
• Ongoing diversification with Cardiac Science, Oncology, Neuro-science, Critical Care,
General Medicine and Transplants

Prudent Capital Allocation

• Sustainable Capex business model
whereby becoming a preferred O&M
Growth in Occupancy Rate
partner on revenue sharing mode
Leadership position • Additional 40% of the total bed capacity is
• Focus to doubling ROCE in coming year in Arthroplasty available to support organic growth trajectory with
due to operational leverage
limited capex

Shalby
24x7 Homecare Services Hospital
• Provide Quality Services Through Training and Development
High-end digital systems 05 • Investment in high impact training
• Growing no of services and markets programs will establish a dedicated
outside home locations professional medical base
04

Leveraging Technology
Expansion Plan
• Adoption and leveraging technology to
• Nashik and Mumbai hospitals within development budget
provide better medical outcomes,
and provide access to important local markets 20
patient reach and satisfaction
FRANCHISE BUSINESS

21
Leveraging Expertise Through Franchise Asset Light Model

Franchise model will leverage Shalby expertise and enable to penetrate faster across pan-India

Business models SOCE Performance in Q2 FY25

Franchise Owned – Shalby Operated (FOSO) Revenue (in ₹ mn) FOSO FOSM Total

1. The franchise is responsible for setting up the centre and Q2-25 23.64 9.93 33.57
SHALBY will be responsible for running the day-to-day
operations. Q2-24 20.74 9.86 30.60
2. Investments for operational expenses and New medical
Equipment by Shalby YOY Growth 13.98% 0.71% 9.71%

Franchise Owned – Shalby Managed (FOSM)

New Operationalised Centre
1. Franchisee sets up SOCE Centre. The Operations are
Location Bed capacity Business Model
managed with a Shalby Appointed Unit Manager
Rajkot* 30 FOSO
2. Centre operated as per Shalby SOP wrt clinical / non-clinical /
admin / Purchase / SCM ❖ Unit operationalised in Rajkot - July’24

3. Investment for all Operational Expenses / New medical

equipments by Franchisee.

22
SHALBY ACADEMY

23
Shalby Academy
Q2 FY25 highlights
Students Enrolled (In Nos)
1. Around 1135 new students registered in Q2 FY24-25 in various
disciplines like Physiotherapy, Nursing, Lab Technician Nutrition & and
dietetics, Clinical, Paramedics, Hospital Management, and Pharmacy as 2,062
part of their academic outreach and up-grade their skills know as 1,716
internships, clinical exposure etc. 1,454
2. New Students have been registered for various Paramedic courses like 1,129 1,142
Lab Technicians, OT Technicians, MRI, CT, and XRAY, etc. The
enrolment process is still on. 419
3. Overall 100 Enrolments for Team Indore (YTD). Total Paramedics
Enrolments for the FY24-25 are 186+ enrolments as on 30th
September,2024. FY 19 FY 20 FY 21 FY 22 FY 23 FY 24
4. Successfully completed enrolments process of MBAHHM Program
(Ganpat University) – Batch 4 with 34 Enrollments for the academic • 30+ Healthcare related courses • Equipped with digital LMS
year 24-26. Successfully launched 1st batch of Kaushalya The • Dedicated Simulation Lab • In association with various
• In-house Clinical Experts healthcare Institutes
University`s Diploma & MSc courses with 26 Students.

Domestic and International Partnership

GANPAT UNIVERSITY - MBAHHM 4th Batch (AY 24-26) Orientation Program 24

@ Shalby Naroda
IMPLANT BUSINESS

25
Diversified into Knee and Hip Implant Manufacturing In California, USA

Backward integration in Orthopedics with Inhouse capacity to consume in India

80,000+
Vertically integrated In-
Components High Quality US FDA
house manufacturing
Manufacturing Approved Implants
Facility
capacity

Surgeon’s Training
~30 Years of Zero
Made in USA and Education
Product Recalls
Program

Seasoned Leadership New Products Presence in USA,

team with decades of - CKS Gold in Q4’25
- Ambition in Q1’26
Japan, India, and
experience in
- Ambition Gold in Q3’26 Indonesia
Orthopedics

26
 Implant Business Performance Q2 FY25

Total Constructs
EBITDA
Revenue Sold
Q2’FY25 Rs. 278 mn Rs. (7.28) mn 3,175+

Q2’FY24 Rs. 147 mn Rs. 2.31 mn 2,170+

Geographical Sales Mix USA Customer Sales Mix Product Sales Mix

Wholesale, Hip
USA, 30% 16%
46%

India, 70%
Retail, 54% Knee
84%

27
SAT 4 PILLARS FOR FY2024-25

SAT STRATEGY
FOR FY2024-25
• New products
Looking for another launch from
8 Mn$ through the Significantly lower Multi-vendor
COGS across
scratch.
right products supply system • Improvement
portfolio by
across SEA with higher in the current
(Malaysia), LATAM improving
efficiencies, shift capacity system.
(5 countries), Russia
times, process, new contributing to • New Design
and other countries
where vendors and our sales products to be
reimbursements are suppliers on forecast. initiated.
higher. boarded.

COGS Capacity increase

SALES NEW PRODUCTS
REDUCTION & Dual SCS

Higher sales & Capacity, Lower COGS

Implant Business Roadmap

Shalby Advanced Technologies plans to become a Global player in a phased manner

Existing Phase 1 Phase 2 Phase 3

Market

Latin America Middle East Countries East Africa

North America
• Argentina • UAE • Kenya
• Columbia • Saudi Arabia • Ethiopia
Japan South-East and North • Oman • Tanzania
Asian Countries CIS Countries
• Malaysia
India
• Korea
South Asian Countries
Indonesia • Bangladesh
• Nepal

Currently we are in Phase-1

29
ABOUT SHALBY

30
Shalby At A Glance

OPD clinics

Presence
16 60 23 Orthopedic Implant
Hospitals1 Domestic International2 Manufacturing in USA

30
Strength
2,350+ 4,600+ 1,150+ Years of Legacy
Bed Capacity Total Employees3 Doctors4 Team

Clinical
Excellence #1
30+ ~3.3 million+ 150,000+ Global Ranking in
Specialties Patients Served 5 Joint Replacements Arthroplasty

1. 11 Multispecialty and 5 Single Specialty, 2. East African Countries, Iraq, CIS, Dubai, Oman, Bangladesh and Nepal. 3. Including Doctors, 4. Including visiting consultants, 5. Since 31
Inception
 30 Years of ELITE Legacy

Integrity
Highest standards of
transparency
accountability, and
corporate governance
Learning Team-Work
Laser sharp focus on A patient-centric focused
upgrading the skills of team with a great blend of
our team and building experience, diversity, fresh
people capability thinking, with proven
ensuring high levels excellence in service
of patient care

Excellence Empathy
Proven leadership in Creating an
healthcare, setting up equitable healthcare
Centre of Excellence system keeping
to capture massive interests of patients
opportunities
ELITE and families at the
focus

32
 Our Journey & Expansion Plan

• Sanar, Gurugram
130 beds
• Jaipur Shalby, Jaipur (237 beds)
• Acquired 100%
• Naroda Shalby, Ahmedabad (267 beds)
Vijay Shalby, Ahmedabad • Vapi Shalby, Vapi (146 beds) stake in Healers
• • Surat Shalby, Surat (243 beds) • Lucknow SOCE, 40 beds
27 beds • Krishna Shalby, Ahmedabad (220 Hospital Pvt Ltd.
• Zynova1 Shalby, Mumbai (100 beds) • Gwalior SOCE, 50 beds
beds)
• Rajkot SOCE,
2021 2023 30 beds
2007 2015

1994 2012 2017 2022 2024

• Jabalpur Shalby, Jabalpur (233 beds) • Acquired Implant Manufacturing • Ranchi,

SG Shalby, Ahmedabad
• Indore Shalby, Indore (243 beds) Unit at California, USA 60 beds
201 beds
• Mohali Shalby, Mohali (145 beds) • Udaipur SOCE, 20 beds

Expansion Plan: Mumbai 175 beds & Nashik 146 Beds

Note: 33
1. Zynova is operating on Revenue sharing business model
Hospitals Portfolio

Multispecialty Units (Owned and Operate)

SG Shalby Vapi Shalby Indore Shalby Jaipur Shalby

Krishna Shalby Mohali Shalby Naroda Shalby

Jabalpur Shalby Surat Shalby Sanar Shalby

34
Franchise Hospital Portfolio

Shalby Orthopedics Centre of Excellence (SOCE) Multispecialty

Vijay Shalby Lucknow Shalby Zynova Shalby

(Mumbai)

(Shalby Operated) (Shalby Operated) (Shalby Managed)

Rajkot Shalby Gwalior Shalby Ranchi Shalby

(Shalby Operated) (Shalby Managed) (Shalby Managed)

35
 Biggest Healthcare Corporate Group in Western and Central India

Domestic Presence…...

PUNJAB
▪ Mohali – 145 beds Uttar Pradesh
▪ Lucknow – 40 beds

DELHI
▪ Gurugram – 130 beds

RAJASTHAN
▪ Jaipur – 237 beds

Jharkhand
GUJARAT
Ranchi – 60 beds
▪ Ahmedabad
o SG – 201 beds
o Krishna – 220 beds
o Naroda – 267 beds
Gujarat
Rajkot – 30 beds
▪ Vapi – 146 beds
▪ Surat – 243 beds
Gujarat
Ahmedabad – 27 beds
MADHYA PRADESH
▪ Indore – 243 beds Madhya Pradesh
▪ Jabalpur – 233 beds Gwalior – 50 beds

MAHARASHTRA
▪ Ghatkopar (Zynova) – 100 beds
OPDs Owned Franchise

Note: 36
• Franchise Network- Zynova, Gwalior and Ranchi are under FOSM operating model Vijay, Rajkot and Lucknow is under FOSO operating model
Sustainability Initiatives

ESG Mindset “We at Shalby are embracing sustainability to drive new values to our business”
Community
Connect

410+ Healthcare Camps Trainings

Healthcare Awareness Programs

Workplace Wellness
24750+ Life impacted

850+ and 830+ Man Hours

Clinical and Non-Clinical training
160+ Healthcare Talks
8700+ participation

Gender Diversity
70+ Healthcare awareness videos
60+ long and short videos as part of
YouTube partnership project so far Workforce
Male- 57% Female-43% Training

37
 Shalby Awards and Accolades in Q2’FY25

News18 Rajasthan Award for Onco- Economic Times Award for Hospital TOI - Times healthcare leaders - 2024 to SG TIMES Healthcare leaders - Service
Sciences to Jaipur Shalby Chain of the Year West to Shalby Multi & Krishna Shalby Excellence in Comprehensive Cancer care
Specialty Hospitals Certificate to Naroda Shalby

Economic Times for Multi-Speciality Tourism Awards 2024 - Best Medical Mid Day Certificate - Ranked Best
Multi Specialty Hospital in Mumbai News18 Rajasthan Award for Neuro 38
Hospital of the Year to Jaipur Shalby Tourism Centre of Gujarat to Shalby
Hospitals and Suburbs to Zynova Shalby Sciences to Jaipur Shalby
Experienced Board Of Directors

Dr. Ashok Bhatia Mr. Tej Malhotra Ms. Sujana Shah

Independent Independent Independent
Director Director Director

Dr. Ashok Bhatia, a senior pharma professional has Mr. Malhotra boasts four decades of international and Mrs. Sujana Shah, a practicing Chartered Accountant
over 40 of professional experience in India and Indian industry experience. Past roles include Senior has vast experience of nearly two decades across the
Emerging Markets. In the past, he was President, Executive Director at GHCL, Technical Director in a domain of finance, accounts, audit, direct and indirect
Emerging Markets with Cadila Healthcare. Saudi Calcium Chloride Company, and Executive taxes, banking and treasury. Currently, she serves as a
Currently, he works as an external consultant of Engineer at Hindustan Copper. He's a recipient of partner of V. R. Shah & Associates, Chartered
Dr. Vikram Shah McKinsey & Co and is a visiting faculty member at prestigious awards, including the 'Bhartiya Udyog Accountants. She has also audited many reputed public
Chairman and IIM Ahmedabad, IIM Rohtak and IIT Gandhinagar. Ratan' and 'Bhartiya Gaurav' from esteemed banks in India as Statutory and Internal Auditor.
organizations, alongside the 'Darbari Seth Award 2009'
Managing Director from the Alkali Manufacturers of India for outstanding
soda-ash plant management.

Dr. Vikram Shah, serving as Director of the Department

of Knee Replacement at Shalby Hospitals since 1993
has nearly three decades of vast professional
healthcare experience across the UK, USA and India.
In recognition of his outstanding contribution in the field
of orthopedics for completion of 1,00,000 joint
replacement surgeries, he was conferred with the
‘Times Man of the Year’ Award by Times of India Mr. Shyamal Joshi Dr. Umesh Menon Mr. Vijay Kedia
Group in 2018. Independent Independent Independent
Director Director Director

Dr. Menon has deep expertise in finance and cost

Associated with Shalby Hospitals since 2010, Mr. Mr. Vijay Kedia joined Shalby as an independent director on
Joshi holds a bachelor’s degree in commerce from accounting. He also holds MBA with specialization in
May 18, 2023. He is the Managing Director of Kedia Securities
Finance, and a fellow member of Institute of Cost
Gujarat University and is a member of the ICAI. He Pvt. Ltd. Holding directorships in companies such as Atul
Accountants of India. He has been conferred with the
has huge working experience that spans corporate Limited and Greenline Tea & Exports Ltd, Kedia received a
Doctorate (PhD) in Management. Currently, he also
strategy, fund raising, acquisition, merger, taxation Doctorate in Management Excellence in 2016. His
serves on the board of directors of various other
and accounting among others. Currently, he holds accomplishments include the "SARVOTTAM SAMMAN" in
companies. He is also an international expert and
directorship of various other Companies. 2020, the Shri Babasaheb Ambedkar Award, and the Shri Abdul
trainer for the United Nations Industrial Development
Kalam Award. A well-known figure in the investment
Organization.
community, Kedia has inspired numerous young investors.

39
 DISCLAIMER and CONTACT DETAILS

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information
or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on
historical information or facts and may be “forward looking statements”, including those relating to the Company’s general business plans and strategy, its future financial
condition and growth prospects, and future developments in its industry and its competitive and regulatory environment. Actual results may differ materially from these
forward-looking statements due to a number of factors, including future changes or developments in the Company’s business, its competitive environment and political,
economic, legal and social conditions in India. This communication is for general information purpose only, without regard to specific objectives, financial situations and needs
of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form
the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of
this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and/or disseminated in any manner.

For further information, please contact:

Jigar Todi
Investors Relation & Corporate Strategy

+91 9512049871
[email protected]

SHALBY LIMITED I Regd Off: Opp. Karnavati Club, S.G. Road, Ahmedabad – 380015, Gujarat, India. Phone: 079 4020 3000 Fax: +91 79 4020 3109 |
Website: www.shalby.org | CIN: L85110GJ2004PLC044667

www.shalby.org 40
40